Argyrios Ziogas

Professor

University of California, Irvine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Background: Alcoholic beverages and the main metabolite of alcohol, acetaldehyde, are known carcinogens. A genetic variant in aldehyde dehydrogenase 2 (ALDH2, G>A, rs671) leads to decreased efficiency in metabolizing acetaldehyde and is associated with an increased cancer risk. As alcohol consumption is a modifiable risk factor for various cancers, the identification of ALDH2 deficiency presents an opportunity for precision cancer prevention. Methods: Our primary objectives were to examine the prevalence of ALDH2 deficiency and alcohol consumption behavior among affected individuals within a large, diverse US national cohort. The prevalence of ALDH2 deficiency was determined by examining the rs671 genotype among 311,290 participants within the All of Us Research Program. Relationships among self-reported alcohol consumption, sociodemographic factors, and the rs671 genotype were analyzed. Results: ALDH2 deficiency was most prevalent among individuals who identified as Asian, among whom 23.5% had at least one deficient ALDH2 allele compared with <2.5% in all other racial/ethnic groups. Among those with one and two deficient ALDH2 alleles, 61.2% and 24.4% reported drinking in the past year, respectively, and of these, 30.3% and 16.0% reported binge drinking. Multivariable analysis showed that ALDH2 genotype, sex, age, race, education, income, employment, marital status, and country of birth were associated with alcohol consumption behavior. Conclusions: Most individuals with ALDH2 deficiency reported drinking alcohol in the past year, and consumption was associated with various sociodemographic variables, particularly sex, age, and country of birth. Impact: Our findings suggest a significant opportunity for precision cancer prevention targeting the unique prevalence of ALDH2 deficiency among Asian Americans.

Year:

2025

Supplementary Table S4 presents results from logistic regression analyses examining factors associated with alcohol consumption and binge drinking. The analyses were conducted separately for the overall cohort and for ALDH2*2 carriers only.

Year:

2025

Supplementary Table S1 outlines how variables were recategorized from the original survey responses. It shows the final categories used in our analysis (left column) and maps them to the corresponding response options from the All of Us Research Program survey questions (right column).

Year:

2025

Background: Alcoholic beverages and the main metabolite of alcohol, acetaldehyde, are known carcinogens. A genetic variant in aldehyde dehydrogenase 2 ( ALDH2 , G>A, rs671) leads to decreased efficiency in metabolizing acetaldehyde and is associated with an increased cancer risk. As alcohol consumption is a modifiable risk factor for various cancers, the identification of ALDH2 deficiency presents an opportunity for precision cancer prevention. Methods: Our primary objectives were to examine the prevalence of ALDH2 deficiency and alcohol consumption behavior among affected individuals within a large, diverse US national cohort. The prevalence of ALDH2 deficiency was determined by examining the rs671 genotype among 311,290 participants within the All of Us Research Program. Relationships among self-reported alcohol consumption, sociodemographic factors, and the rs671 genotype were analyzed. Results: ALDH2 deficiency was most prevalent among individuals who identified as Asian, among whom 23.5% had at least one deficient ALDH2 allele compared with ALDH2 alleles, 61.2% and 24.4% reported drinking in the past year, respectively, and of these, 30.3% and 16.0% reported binge drinking. Multivariable analysis showed that ALDH2 genotype , sex, age, race, education, income, employment, marital status, and country of birth were associated with alcohol consumption behavior. Conclusions: Most individuals with ALDH2 deficiency reported drinking alcohol in the past year, and consumption was associated with various sociodemographic variables, particularly sex, age, and country of birth. Impact: Our findings suggest a significant opportunity for precision cancer prevention targeting the unique prevalence of ALDH2 deficiency among Asian Americans.

Year:

2025

Supplementary Table S4 presents results from logistic regression analyses examining factors associated with alcohol consumption and binge drinking. The analyses were conducted separately for the overall cohort and for ALDH2*2 carriers only.

Year:

2025

Supplementary Methods S1 presents a matrix used to categorize participants' alcohol consumption based on two survey questions: their frequency of alcohol consumption in the past year (columns) and their typical number of drinks consumed per drinking occasion (rows).

Year:

2025

Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). Experimental Design: Germline PV frequencies in breast cancer predisposition genes ( ATM , BARD1 , BRCA1 , BRCA2 , CDH1 , CHEK2 , PALB2 , RAD51C , and RAD51D ) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort ( n = 9,887), a population-based cohort ( n = 3,876), and the UK Biobank ( n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort. Results: Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1 , BRCA2 , and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years. Conclusions: The enrichment of PV in ATM , BRCA1 , BRCA2 , CHEK2 , and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.

Year:

2025

Background: Literature on colorectal cancer (CRC) outcomes in individuals of Middle Eastern and North African (MENA) descent is limited. To address this gap, we estimated five-year CRC-specific survival by race and ethnicity, including MENA individuals, in a diverse, population-based sample in California. Methods: We identified adults (ages 18-79 years) diagnosed with a first or only CRC in 2004 – 2017 using the California Cancer Registry, including non-Hispanic White, non-Hispanic Black, non-Hispanic Asian, Hispanic, and MENA individuals. For each racial/ethnic group, we calculated five-year CRC-specific survival and used Cox proportional hazards regression models to examine the association of race/ethnicity and survival, adjusting for clinical and sociodemographic factors. Results: Of 110,192 persons diagnosed with CRC, five-year CRC-specific survival was lowest in Black (61.0%) and highest in MENA (73.2%) individuals. Asian (72.2%) individuals had higher survival than White (70.0%) and Hispanic (68.2%) individuals. In adjusted analysis, MENA (aHR 0.82, 95% CI 0.76, 0.89), Asian (aHR 0.86, 95% CI 0.83, 0.90), and Hispanic (aHR 0.94, 95% CI 0.91, 0.97) race/ethnicity were associated with higher, and Black (aHR 1.13, 95% CI 1.09, 1.18) race/ethnicity was associated with lower, survival compared to non-Hispanic White race/ethnicity. Conclusion: To our knowledge, this is the first study to report CRC survival in MENA individuals in the U.S. We observed higher survival of MENA individuals compared to other racial/ethnic groups, adjusting for sociodemographic and clinical factors. Impact: Future studies are needed to identify factors contributing to cancer outcomes in this unique population. Keywords: colorectal cancer; survival; Middle Eastern; race/ethnicity; population-based

Year:

2024

Background: Literature on colorectal cancer outcomes in individuals of Middle Eastern and North African (MENA) descent is limited. To address this gap, we estimated five-year colorectal cancer–specific survival by race and ethnicity, including MENA individuals, in a diverse, population-based sample in California. Methods: We identified adults (ages 18–79 years) diagnosed with a first or only colorectal cancer in 2004 to 2017 using the California Cancer Registry (CCR), including non-Hispanic White, non-Hispanic Black, non-Hispanic Asian, Hispanic, and MENA individuals. For each racial/ethnic group, we calculated five-year colorectal cancer–specific survival and used Cox proportional hazards regression models to examine the association of race/ethnicity and survival, adjusting for clinical and socio demographic factors. Results: Of 110,192 persons diagnosed with colorectal cancer, five-year colorectal cancer–specific survival was lowest in Black (61.0%) and highest in MENA (73.2%) individuals. Asian (72.2%) individuals had higher survival than White (70.0%) and Hispanic (68.2%) individuals. In adjusted analysis, MENA [adjusted HR (aHR), 0.82; 95% confidence interval (CI), 0.76–0.89], Asian (aHR, 0.86; 95% CI, 0.83–0.90), and Hispanic (aHR, 0.94; 95% CI, 0.91–0.97) race/ethnicity were associated with higher, and Black (aHR, 1.13; 95% CI, 1.09–1.18) race/ethnicity was associated with lower survival compared with non-Hispanic White race/ethnicity. Conclusions: To our knowledge, this is the first study to report colorectal cancer survival in MENA individuals in the United States. We observed higher survival of MENA individuals compared with other racial/ethnic groups, adjusting for sociodemographic and clinical factors. Impact: Future studies are needed to identify factors contributing to cancer outcomes in this unique population.

Year:

2024

Background: Literature on colorectal cancer outcomes in individuals of Middle Eastern and North African (MENA) descent is limited. To address this gap, we estimated five-year colorectal cancer–specific survival by race and ethnicity, including MENA individuals, in a diverse, population-based sample in California. Methods: We identified adults (ages 18–79 years) diagnosed with a first or only colorectal cancer in 2004 to 2017 using the California Cancer Registry (CCR), including non-Hispanic White, non-Hispanic Black, non-Hispanic Asian, Hispanic, and MENA individuals. For each racial/ethnic group, we calculated five-year colorectal cancer–specific survival and used Cox proportional hazards regression models to examine the association of race/ethnicity and survival, adjusting for clinical and socio demographic factors. Results: Of 110,192 persons diagnosed with colorectal cancer, five-year colorectal cancer–specific survival was lowest in Black (61.0%) and highest in MENA (73.2%) individuals. Asian (72.2%) individuals had higher survival than White (70.0%) and Hispanic (68.2%) individuals. In adjusted analysis, MENA [adjusted HR (aHR), 0.82; 95% confidence interval (CI), 0.76–0.89], Asian (aHR, 0.86; 95% CI, 0.83–0.90), and Hispanic (aHR, 0.94; 95% CI, 0.91–0.97) race/ethnicity were associated with higher, and Black (aHR, 1.13; 95% CI, 1.09–1.18) race/ethnicity was associated with lower survival compared with non-Hispanic White race/ethnicity. Conclusions: To our knowledge, this is the first study to report colorectal cancer survival in MENA individuals in the United States. We observed higher survival of MENA individuals compared with other racial/ethnic groups, adjusting for sociodemographic and clinical factors. Impact: Future studies are needed to identify factors contributing to cancer outcomes in this unique population.

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (26)

Danielle Forman

Chief Scribe

ScribeAmerica

UNITED STATES
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Christine Ambrosone

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Song Yao

Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Katie O'Brien

Staff Scientist

National Institute of Environmental Health Sciences

UNITED STATES
View details

A Heather Eliassen

Professor

Harvard University

UNITED STATES
View details

Dale Sandler

Branch Chief

National Institute of Environmental Health Sciences

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Clarice Weinberg

Principal Investigator

National Institute of Environmental Health Sciences

UNITED STATES
View details

Peter Kraft

Professor

Harvard T.H. Chan School of Public Health

UNITED STATES
View details

Manxi Yang

University of California, Irvine

UNITED STATES
View details

Siddhartha Yadav

Associate Professor of Oncology

Mayo Clinic

UNITED STATES
View details

Maria Elena. Martinez

University of California

UNITED STATES
View details

Esther John

Professor

Stanford University School of Medicine

UNITED STATES
View details

Jeffrey Weitzel

Professor and Director

University of Kansas Cancer Center

UNITED STATES
View details

Trina Norden-Krichmar

University of California

UNITED STATES
View details

Hoda Anton-Culver

Professor and Chair

University of California, Irvine

UNITED STATES
View details

Ryan Chien

Johns Hopkins University

UNITED STATES
View details

Caitlin Murphy

Associate Professor

The University of Texas Health Science Center at Houston

UNITED STATES
View details

Hannah Lui Park

Associate Professor

University of California

UNITED STATES
View details

Kathryn Ruddy

Professor

Mayo Clinic

UNITED STATES
View details

Kimberly A. Bertrand

Associate Professor of Medicine

Boston University

UNITED STATES
View details

Eric Polley

Associate Professor

University of Chicago

UNITED STATES
View details

Nicholas Boddicker

Research Associate

Mayo Clinic

UNITED STATES
View details